CDXI - Cardax, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0600
-0.0050 (-7.69%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.0650
Open0.1239
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0600 - 0.1239
52 Week Range0.0520 - 0.2200
Volume221,174
Avg. Volume30,920
Market Cap8.198M
Beta (3Y Monthly)0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings DateMay 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • PR Newswire

    Cardax Announces Interim Results from CHASE Clinical Trial

    Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health - CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced - Interim results ...

  • PR Newswire

    Cardax Reports Q2 2019 Results

    HONOLULU, Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) today filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. Cardax plans a pre-specified interim review in September 2019 of the aggregate data by treatment group from its CHASE human clinical trial.

  • PR Newswire

    Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering

    HONOLULU, Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of up to $15 million of the Company's common stock and warrants. The number of securities to be offered and the price range for the offering have not yet been determined.

  • PR Newswire

    Cardax Reports Q1 2019 Results

    HONOLULU, May 17, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC. Cardax continued to make progress in Q1 2019 across its primary areas of focus: the ZanthoSyn® consumer health business, CHASE human clinical trial, and Rx development programs. Q1 2019 represented the top performing quarter, as measured in dollars and units, for retail sales of ZanthoSyn® to customers at General Nutrition Corporation ("GNC") stores ("sell-through") since ZanthoSyn®'s launch at GNC in Q1 2017.

  • PR Newswire

    Cardax Reports 2018 Results

    HONOLULU, March 28, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC. The increase in revenues primarily reflects the strong sell-through of ZanthoSyn® in General Nutrition Corporation ("GNC") stores in Hawaii as well as in California, Nevada, and New York where the Company has focused its sales and marketing efforts to date. The Company plans to expand its sales and marketing efforts to other major markets in 2019 as resources permit.

  • PR Newswire

    Cardax to Present at NobleCon XV

    LEADING SMALL CAP/MICRO CAP CONFERENCE FEATURES 600 ATTENDEES HONOLULU , Jan. 25, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced ...

  • PR Newswire

    Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program

    HONOLULU, Dec. 3, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) and GNC (GNC) announced today that they are expanding the sales and marketing program for ZanthoSyn®, Cardax's premium astaxanthin dietary supplement for inflammatory health and longevity. GNC is the exclusive brick-and-mortar retail channel for ZanthoSyn®.

  • PR Newswire

    Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy

    HONOLULU, Nov. 28, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced that Paresh N. Soni, M.D., Ph.D., the former Senior Vice President and Head of Development for Amarin Corporation, will join Cardax as Chief Clinical and Regulatory Strategist and as a member of the Company's Scientific Advisory Board. Dr. Soni will guide clinical and regulatory strategy for Cardax's pharmaceutical platform, interact with the FDA, and advise the Company on a full range of development issues.

  • PR Newswire

    Cardax Reports Q3 2018 Results

    HONOLULU, Nov. 13, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced its results for the third quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased 102% from $272,049 in Q2 2018 to $549,540 in Q3 2018. Q3 2017 had the largest ZanthoSyn® revenues in 2017, primarily reflecting the first nationwide stocking orders from GNC, the Company's exclusive U.S. "brick-and-mortar" retail channel.